← All indications
Phobia, Social
Anxiety disorder characterized by the persistent and irrational fear, anxiety, or avoidance of social or performance situations.
Drugs by status
Approved for this indication (3)
Phase 4 trials (17)
Phase 3 trials (10)
Phase 2 trials (12)
Phase 1 trials (6)
Organizations
Organization Involved with Phase 4 Indications (33)
- Cephalon
- Bristol-Myers Squibb
- AstraZeneca
- Eli Lilly
- Pfizer
- Purdue Pharmaceuticals
- Hamilton Health Sciences Corporation
- National Institutes of Health (NIH)
- National Institute of Mental Health (NIMH)
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- Boston University
- Harvard University
- Emory University
- Georgetown University
- University of Washington
- Hoosier Cancer Research Network
- Mclean Hospital
- McMaster University
- Rutgers University
- Southern Methodist University
- University of Medicine and Dentistry of New Jersey
- University of South Carolina
- Columbia University
- University of California, Los Angeles
- University of California, San Diego
- Medical University of South Carolina
- University of Minnesota
- The Medical Research Network, LLC
- Janssen Pharmaceutica NV
- RAND Corporation
- +3 more
Organization Involved with Phase 3 Indications (14)
- Wyeth
- GlaxoSmithKline
- Pherin Pharmaceuticals, Inc.
- Tilray
- National Center for Complementary and Integrative Health (NCCIH)
- Duke University
- Temple University
- Johns Hopkins University
- START Clinic for Mood and Anxiety Disorders
- Yale University
- State University of New York
- University of Central Florida
- State University of New York, Syracuse
- Biohaven Pharmaceuticals Inc.
Organization Involved with Phase 2 Indications (9)
Organization Involved with Phase 1 Indications (5)
Organization Involved with Other Experimental Indications (2)